BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Christians KK, Heimler JW, George B, Ritch PS, Erickson BA, Johnston F, Tolat PP, Foley WD, Evans DB, Tsai S. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Surgery. 2016;159:893-900. [PMID: 26602840 DOI: 10.1016/j.surg.2015.09.018] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 14.3] [Reference Citation Analysis]
Number Citing Articles
1 Tsai S, Christians KK, George B, Ritch PS, Dua K, Khan A, Mackinnon AC, Tolat P, Ahmad SA, Hall WA, Erickson BA, Evans DB. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. Annals of Surgery 2018;268:610-9. [DOI: 10.1097/sla.0000000000002957] [Cited by in Crossref: 30] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
2 Maggino L, Vollmer CM Jr. Recent Advances in Pancreatic Cancer Surgery. Curr Treat Options Gastroenterol 2017;15:520-37. [PMID: 28852967 DOI: 10.1007/s11938-017-0150-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
3 Tummers WS, Miller SE, Teraphongphom NT, Gomez A, Steinberg I, Huland DM, Hong S, Kothapalli SR, Hasan A, Ertsey R, Bonsing BA, Vahrmeijer AL, Swijnenburg RJ, Longacre TA, Fisher GA, Gambhir SS, Poultsides GA, Rosenthal EL. Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging. Ann Surg Oncol 2018;25:1880-8. [PMID: 29667116 DOI: 10.1245/s10434-018-6453-2] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 17.0] [Reference Citation Analysis]
4 Okano K, Suto H, Oshima M, Maeda E, Yamamoto N, Kakinoki K, Kamada H, Masaki T, Takahashi S, Shibata T, Suzuki Y. A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2017;24:2777-2784. [PMID: 28608121 DOI: 10.1245/s10434-017-5921-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
5 Barnes CA, Krepline AN, Aldakkak M, Clarke CN, Christians KK, Khan AH, Hunt BC, Ritch PS, George B, Hall WA, Erickson BA, Evans DB, Tsai S. Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy? J Gastrointest Surg. 2017;21:1793-1803. [PMID: 28849366 DOI: 10.1007/s11605-017-3544-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
6 Ren W, Xourafas D, Ashley SW, Clancy TE. Prognostic Factors in Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Resection. Am Surg 2021;:3134821991962. [PMID: 33522271 DOI: 10.1177/0003134821991962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Watson MD, Thompson KJ, Musselwhite LW, Hwang JJ, Baker EH, Martinie JB, Vrochides D, Iannitti DA, Ocuin LM. The treatment sequence may matter in patients undergoing pancreatoduodenectomy for early stage pancreatic cancer in the era of modern chemotherapy. Am J Surg 2021;222:159-66. [PMID: 33121658 DOI: 10.1016/j.amjsurg.2020.10.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kim RY, Evans DB, Christians KK. Locally advanced pancreatic cancer: staging, operability, and the importance of multimodality therapy. Hepatobiliary Surg Nutr 2020;9:497-500. [PMID: 32832502 DOI: 10.21037/hbsn.2019.11.26] [Reference Citation Analysis]
9 Hartmann D, Kaufmann B, Friess H. Surgery for pancreatic disease. Curr Opin Gastroenterol 2016;32:408-14. [PMID: 27428805 DOI: 10.1097/MOG.0000000000000305] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Mirkin KA, Hollenbeak CS, Gusani NJ, Wong J. Trends in utilization of neoadjuvant therapy and short-term outcomes in resected pancreatic cancer. The American Journal of Surgery 2017;214:80-8. [DOI: 10.1016/j.amjsurg.2016.08.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
11 Evans DB. What Makes a Pancreatic Cancer Resectable? Am Soc Clin Oncol Educ Book 2018;38:300-5. [PMID: 30231408 DOI: 10.1200/EDBK_200861] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
12 Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Kawasaki Y, Arigami T, Mori S, Kijima Y, Ueno S, Shinchi H, Natsugoe S. A Therapeutic Strategy for Resectable Pancreatic Cancer Based on Risk Factors of Early Recurrence. Pancreas 2018;47:753-8. [PMID: 29771771 DOI: 10.1097/MPA.0000000000001066] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
13 Younan G, Tsai S, Evans DB, Christians KK. Techniques of Vascular Resection and Reconstruction in Pancreatic Cancer. Surg Clin North Am 2016;96:1351-70. [PMID: 27865282 DOI: 10.1016/j.suc.2016.07.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
14 Crippa S, Cirocchi R, Weiss MJ, Partelli S, Reni M, Wolfgang CL, Hackert T, Falconi M. A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. Updates Surg 2020;72:39-45. [PMID: 31997233 DOI: 10.1007/s13304-020-00710-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
15 Tsai S, Christians KK, Ritch PS, George B, Khan AH, Erickson B, Evans DB. Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease. J Oncol Pract 2016;12:915-23. [PMID: 27858562 DOI: 10.1200/JOP.2016.016162] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
16 Cherkassky L, Jarnagin W. Selecting treatment sequence for patients with incidental gallbladder cancer: a neoadjuvant approach versus upfront surgery. Updates Surg 2019;71:217-25. [PMID: 31254234 DOI: 10.1007/s13304-019-00670-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
17 Asare EA, Evans DB, Erickson BA, Aburajab M, Tolat P, Tsai S. Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer. J Surg Oncol 2016;114:291-5. [PMID: 27264017 DOI: 10.1002/jso.24316] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
18 de Geus SW, Eskander MF, Bliss LA, Kasumova GG, Ng SC, Callery MP, Tseng JF. Neoadjuvant therapy vs upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis. Surgery. 2017;161:592-601. [PMID: 28341441 DOI: 10.1016/j.surg.2016.08.040] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
19 Schorn S, Demir IE, Reyes CM, Saricaoglu C, Samm N, Schirren R, Tieftrunk E, Hartmann D, Friess H, Ceyhan GO. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis. Cancer Treat Rev 2017;55:96-106. [PMID: 28342938 DOI: 10.1016/j.ctrv.2017.03.003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
20 Sahakyan MA, Kim SC, Kleive D, Kazaryan AM, Song KB, Ignjatovic D, Buanes T, Røsok BI, Labori KJ, Edwin B. Laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: Long-term oncologic outcomes after standard resection. Surgery 2017;162:802-11. [PMID: 28756944 DOI: 10.1016/j.surg.2017.06.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
21 Mokdad AA, Minter RM, Zhu H, Augustine MM, Porembka MR, Wang SC, Yopp AC, Mansour JC, Choti MA, Polanco PM. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis. J Clin Oncol. 2017;35:515-522. [PMID: 27621388 DOI: 10.1200/jco.2016.68.5081] [Cited by in Crossref: 178] [Cited by in F6Publishing: 72] [Article Influence: 29.7] [Reference Citation Analysis]
22 Mangieri CW, Strode MA, Moaven O, Clark CJ, Shen P. Utilization of chemoradiation therapy provides strongest protective effect for avoidance of postoperative pancreatic fistula following pancreaticoduodenectomy: A NSQIP analysis. J Surg Oncol 2020;122:1604-11. [PMID: 32935353 DOI: 10.1002/jso.26202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Ocuin LM, Hardacre JM, Ammori JB, Rothermel LD, Mohamed A, Selfridge JE, Bajor D, Winter JM. Neoadjuvant chemotherapy is associated with improved survival in patients with left-sided pancreatic adenocarcinoma. J Surg Oncol 2020;122:1595-603. [PMID: 32844445 DOI: 10.1002/jso.26196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
24 Li X, Guo C, Li Q, Wei S, Zhang Q, Chen Y, Shen Y, Ma T, Li G, Gao S, Que R, Lou J, Yu R, Yuan Y, Wei Q, Huang P, Liang T, Bai X. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population. Oncologist 2019;24:301-e93. [PMID: 30459238 DOI: 10.1634/theoncologist.2018-0696] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
25 Barnes CA, Chavez MI, Tsai S, Aldakkak M, George B, Ritch PS, Dua K, Clarke CN, Tolat P, Hagen C, Hall WA, Erickson BA, Evans DB, Christians KK. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Surgery. 2019;166:277-285. [PMID: 31272811 DOI: 10.1016/j.surg.2019.05.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
26 Tran Cao HS, Zhang Q, Sada YH, Silberfein EJ, Hsu C, Van Buren G, Chai C, Katz MH, Fisher WE, Massarweh NN. Value of lymph node positivity in treatment planning for early stage pancreatic cancer. Surgery 2017;162:557-67. [DOI: 10.1016/j.surg.2017.05.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
27 O'Reilly EM, Ferrone C. Neoadjuvant or Adjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer: Which Is Preferred? J Clin Oncol 2020;38:1757-9. [PMID: 32119598 DOI: 10.1200/JCO.19.03318] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
28 Crippa S, Cirocchi R, Maisonneuve P, Partelli S, Pergolini I, Tamburrino D, Aleotti F, Reni M, Falconi M. Systematic review and meta-analysis of prognostic role of splenic vessels infiltration in resectable pancreatic cancer. Eur J Surg Oncol 2018;44:24-30. [PMID: 29183639 DOI: 10.1016/j.ejso.2017.10.217] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
29 Endo Y, Kitago M, Aiura K, Shinoda M, Yagi H, Abe Y, Oshima G, Hori S, Nakano Y, Itano O, Fukada J, Masugi Y, Kitagawa Y. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study. World J Surg Oncol. 2019;17:145. [PMID: 31420046 DOI: 10.1186/s12957-019-1687-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
30 Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Arigami T, Mori S, Ueno S, Shinchi H, Takao S, Natsugoe S. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma. Pancreatology 2016;16:1051-6. [DOI: 10.1016/j.pan.2016.09.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Buanes TA. Role of surgery in pancreatic cancer. World J Gastroenterol 2017; 23(21): 3765-3770 [PMID: 28638216 DOI: 10.3748/wjg.v23.i21.3765] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
32 Borhani AA, Dewan R, Furlan A, Seiser N, Zureikat AH, Singhi AD, Boone B, Bahary N, Hogg ME, Lotze M, Zeh HJ III, Tublin ME. Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. AJR Am J Roentgenol. 2020;214:362-369. [PMID: 31799875 DOI: 10.2214/ajr.19.21152] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
33 Barnes CA, Aldakkak M, Christians KK, Clarke CN, Dua K, George B, Ritch PS, Kamgar M, Hall WA, Kulkarni N, Erickson BA, Evans DB, Tsai S. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer. Surgery 2020;168:440-7. [DOI: 10.1016/j.surg.2020.04.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
34 Wolff RA. Adjuvant or Neoadjuvant Therapy in the Treatment in Pancreatic Malignancies: Where Are We? Surg Clin North Am 2018;98:95-111. [PMID: 29191281 DOI: 10.1016/j.suc.2017.09.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
35 Shin IS, Moon JH, Lee YN, Chung JC, Jeong J, Choi SY, Lee TH, Yang JK, Cha SW, Cho YD, Park SH. Modified non-flared fully covered self-expandable metal stent for preoperative biliary drainage in pancreatic cancer. J Gastroenterol Hepatol 2021. [PMID: 34750863 DOI: 10.1111/jgh.15733] [Reference Citation Analysis]
36 Brown ZJ, Cloyd JM. Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma. J Surg Oncol. 2021;123:1432-1440. [PMID: 33831253 DOI: 10.1002/jso.26384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Van Sciver RE, Lee MP, Lee CD, Lafever AC, Svyatova E, Kanda K, Colliver AL, Siewertsz van Reesema LL, Tang-Tan AM, Zheleva V, Bwayi MN, Bian M, Schmidt RL, Matrisian LM, Petersen GM, Tang AH. A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology. Cancers (Basel) 2018;10:E142. [PMID: 29757973 DOI: 10.3390/cancers10050142] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
38 Aaltonen P, Carpén O, Mustonen H, Puolakkainen P, Haglund C, Peltola K, Seppänen H. Long-term nationwide trends in the treatment of and outcomes among pancreatic cancer patients. Eur J Surg Oncol 2021:S0748-7983(21)00925-2. [PMID: 34844817 DOI: 10.1016/j.ejso.2021.11.116] [Reference Citation Analysis]
39 Xia BT, Habib DA, Dhar VK, Levinsky NC, Kim Y, Hanseman DJ, Sutton JM, Wilson GC, Smith M, Choe KA, Sussman JJ, Ahmad SA, Abbott DE. Early Recurrence and Omission of Adjuvant Therapy after Pancreaticoduodenectomy Argue against a Surgery-First Approach. Ann Surg Oncol 2016;23:4156-64. [PMID: 27459987 DOI: 10.1245/s10434-016-5457-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
40 Cloyd JM, Chen H, Wang X, Tzeng CD, Kim MP, Aloia TA, Vauthey J, Lee JE, Katz MH. Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Adjusted Analysis. Pancreas 2019;48:216-22. [DOI: 10.1097/mpa.0000000000001231] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 9.3] [Reference Citation Analysis]
41 Perone JA, Riall TS, Olino K. Palliative Care for Pancreatic and Periampullary Cancer. Surg Clin North Am 2016;96:1415-30. [PMID: 27865285 DOI: 10.1016/j.suc.2016.07.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
42 Petrucciani N, Debs T, Nigri G, Giannini G, Sborlini E, Kassir R, Ben Amor I, Iannelli A, Valabrega S, D'Angelo F, Gugenheim J, Ramacciato G. Pancreatectomy combined with multivisceral resection for pancreatic malignancies: is it justified? Results of a systematic review. HPB (Oxford). 2018;20:3-10. [PMID: 28943396 DOI: 10.1016/j.hpb.2017.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
43 Evans DB, Kamgar M, Tsai S. Goals of Treatment Sequencing for Localized Pancreatic Cancer. Ann Surg Oncol 2019;26:3815-9. [DOI: 10.1245/s10434-019-07738-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
44 Tsai S, McOlash L, Jia S, Zhang J, Simpson P, Kaldunski ML, Aldakkak M, Grewal J, Palen K, Dwinell MB, Johnson BD, Mackinnon A, Hessner MJ, Gershan JA. A Serum-Induced Transcriptome and Serum Cytokine Signature Obtained at Diagnosis Correlates with the Development of Early Pancreatic Ductal Adenocarcinoma Metastasis. Cancer Epidemiol Biomarkers Prev 2019;28:680-9. [PMID: 30530849 DOI: 10.1158/1055-9965.EPI-18-0813] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
45 Marchegiani G, Andrianello S, Malleo G, De Gregorio L, Scarpa A, Mino-kenudson M, Maggino L, Ferrone CR, Lillemoe KD, Bassi C, Castillo CF, Salvia R. Does Size Matter in Pancreatic Cancer?: Reappraisal of Tumour Dimension as a Predictor of Outcome Beyond the TNM. Annals of Surgery 2017;266:142-8. [DOI: 10.1097/sla.0000000000001837] [Cited by in Crossref: 46] [Cited by in F6Publishing: 28] [Article Influence: 9.2] [Reference Citation Analysis]
46 Borazanci E, Sckolnik S, Amini A. Neo-adjuvant therapy for pancreatic cancer: hope for the future. Expert Rev Gastroenterol Hepatol 2019;13:579-89. [PMID: 30979348 DOI: 10.1080/17474124.2019.1607294] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
47 Vreeland TJ, Katz MHG. Timing of Pancreatic Resection and Patient Outcomes: Is There a Difference? Surg Clin North Am 2018;98:57-71. [PMID: 29191278 DOI: 10.1016/j.suc.2017.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
48 Hue JJ, Markt SC, Sugumar K, Kyasaram RK, Shanahan J, Rothermel LD, Ammori JB, Hardacre JM, Winter JM, Ocuin LM. Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. Am J Surg 2021:S0002-9610(21)00564-X. [PMID: 34642044 DOI: 10.1016/j.amjsurg.2021.10.001] [Reference Citation Analysis]
49 Taboada AGM, Lominchar PL, Roman LM, García-Alfonso P, Martin AJM, Rodriguez JAB, Pascual JMA. Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades. Ann Hepatobiliary Pancreat Surg 2021;25:179-91. [PMID: 34053920 DOI: 10.14701/ahbps.2021.25.2.179] [Reference Citation Analysis]
50 Labori KJ, Lassen K, Hoem D, Grønbech JE, Søreide JA, Mortensen K, Smaaland R, Sorbye H, Verbeke C, Dueland S. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial. BMC Surg 2017;17:94. [PMID: 28841916 DOI: 10.1186/s12893-017-0291-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 8.6] [Reference Citation Analysis]
51 Nappo G, Donisi G, Zerbi A. Borderline resectable pancreatic cancer: Certainties and controversies. World J Gastrointest Surg 2021; 13(6): 516-528 [PMID: 34194610 DOI: 10.4240/wjgs.v13.i6.516] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Chatzizacharias NA, Tsai S, Griffin M, Tolat P, Ritch P, George B, Barnes C, Aldakkak M, Khan AH, Hall W, Erickson B, Evans DB, Christians KK. Locally advanced pancreas cancer: Staging and goals of therapy. Surgery 2018;163:1053-62. [PMID: 29331400 DOI: 10.1016/j.surg.2017.09.012] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
53 Barnes CA, Aldakkak M, Clarke CN, Christians KK, Bucklan D, Holt M, Tolat P, Ritch PS, George B, Hall WA, Erickson BA, Evans DB, Tsai S. Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy. Front Oncol. 2020;10:500. [PMID: 32363161 DOI: 10.3389/fonc.2020.00500] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
54 Rieser CJ, Narayanan S, Bahary N, Bartlett DL, Lee KK, Paniccia A, Smith K, Zureikat AH. Optimal management of patients with operable pancreatic head cancer: A Markov decision analysis. J Surg Oncol 2021. [PMID: 34231222 DOI: 10.1002/jso.26589] [Reference Citation Analysis]
55 Unno M, Hata T, Motoi F. Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis. Surg Today. 2019;49:295-299. [PMID: 30877550 DOI: 10.1007/s00595-019-01786-w] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
56 Kim SM, Eads JR. Adjuvant and Neoadjuvant Therapy for Resectable Pancreatic and Periampullary Cancer. Surg Clin North Am. 2016;96:1287-1300. [PMID: 27865278 DOI: 10.1016/j.suc.2016.07.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
57 Gugenheim J, Crovetto A, Petrucciani N. Neoadjuvant therapy for pancreatic cancer. Updates Surg 2021. [PMID: 34628591 DOI: 10.1007/s13304-021-01186-1] [Reference Citation Analysis]
58 Blair AB, Sorber R, Rozich NS, Burkhart RA. A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma. Pancreas 2019;48:973-84. [DOI: 10.1097/mpa.0000000000001376] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
59 de Geus SWL, Kasumova GG, Eskander MF, Ng SC, Kent TS, James Moser A, Vahrmeijer AL, Callery MP, Tseng JF. Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study. J Gastrointest Surg 2018;22:214-25. [PMID: 29235000 DOI: 10.1007/s11605-017-3541-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
60 Tsai S, George B, Wittmann D, Ritch PS, Krepline AN, Aldakkak M, Barnes CA, Christians KK, Dua K, Griffin M, Hagen C, Hall WA, Erickson BA, Evans DB. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Ann Surg. 2020;271:740-747. [PMID: 30312198 DOI: 10.1097/sla.0000000000003049] [Cited by in Crossref: 40] [Cited by in F6Publishing: 21] [Article Influence: 20.0] [Reference Citation Analysis]
61 Ballard DD, Rahman S, Ginnebaugh B, Khan A, Dua KS. Safety and efficacy of self-expanding metal stents for biliary drainage in patients receiving neoadjuvant therapy for pancreatic cancer. Endosc Int Open 2018;6:E714-21. [PMID: 29868636 DOI: 10.1055/a-0599-6190] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
62 Ward EP, Evans DB, Tsai S. Ten-year experience in optimizing neoadjuvant therapy for localized pancreatic cancer-Medical college of Wisconsin perspective. J Surg Oncol 2021;123:1405-13. [PMID: 33831252 DOI: 10.1002/jso.26395] [Reference Citation Analysis]
63 Kim HS, Jang JY, Han Y, Lee KB, Joo I, Lee DH, Kim JR, Kim H, Kwon W, Kim SW. Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer. Ann Surg Treat Res 2017;93:186-94. [PMID: 29094028 DOI: 10.4174/astr.2017.93.4.186] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
64 Zettervall SL, Ju T, Holzmacher JL, Huysman B, Werba G, Sidawy A, Lin P, Vaziri K. Arterial, but Not Venous, Reconstruction Increases 30-Day Morbidity and Mortality in Pancreaticoduodenectomy. J Gastrointest Surg 2020;24:578-84. [PMID: 30945084 DOI: 10.1007/s11605-019-04211-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
65 Araujo RLC, Silva RO, de Pádua Souza C, Milani JM, Huguet F, Rezende AC, Gaujoux S. Does neoadjuvant therapy for pancreatic head adenocarcinoma increase postoperative morbidity? A systematic review of the literature with meta-analysis. J Surg Oncol 2020;121:881-92. [PMID: 31994193 DOI: 10.1002/jso.25851] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
66 Xu JZ, Wang WQ, Zhang SR, Xu HX, Wu CT, Qi ZH, Gao HL, Li S, Ni QX, Yu XJ, Liu L. Neoadjuvant Therapy is Essential for Resectable Pancreatic Cancer. Curr Med Chem. 2019;26:7196-7211. [PMID: 29651946 DOI: 10.2174/0929867325666180413101722] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
67 Hue JJ, Katayama E, Sugumar K, Winter JM, Ammori JB, Rothermel LD, Hardacre JM, Ocuin LM. The importance of multimodal therapy in the management of nonmetastatic adenosquamous carcinoma of the pancreas: Analysis of treatment sequence and strategy. Surgery 2021;169:1102-9. [PMID: 33376004 DOI: 10.1016/j.surg.2020.11.026] [Reference Citation Analysis]
68 Jariwalla NR, Khan AH, Dua K, Christians KK, Clarke CN, Aldakkak M, George B, Tutton S, Rilling W, Erickson B, Evans DB, Tsai S. Management of Acute Cholecystitis during Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma. Ann Surg Oncol 2019;26:4515-21. [DOI: 10.1245/s10434-019-07906-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
69 Vitello DJ, Bentrem DJ. A review of response in neoadjuvant therapy for exocrine pancreatic cancer. J Surg Oncol 2021;123:1449-59. [PMID: 33831249 DOI: 10.1002/jso.26369] [Reference Citation Analysis]
70 Kim JK, DePeralta DK, Ogami T, Denbo JW, Pimiento J, Hodul PJ, Malafa MP, Kim DW, Fleming JB, Powers BD. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis. J Surg Oncol 2020;122:1074-83. [PMID: 32673436 DOI: 10.1002/jso.26103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Mollinedo F, Gajate C. Direct Endoplasmic Reticulum Targeting by the Selective Alkylphospholipid Analog and Antitumor Ether Lipid Edelfosine as a Therapeutic Approach in Pancreatic Cancer. Cancers (Basel) 2021;13:4173. [PMID: 34439330 DOI: 10.3390/cancers13164173] [Reference Citation Analysis]
72 Christians KK, Evans DB. Pancreaticoduodenectomy and Vascular Reconstruction: Indications and Techniques. Surg Oncol Clin N Am 2021;30:731-46. [PMID: 34511193 DOI: 10.1016/j.soc.2021.06.011] [Reference Citation Analysis]
73 Tsai S, Erickson BA, Dua K, Ritch PS, Tolat P, Evans DB. Evolution of the Management of Resectable Pancreatic Cancer. JOP 2016;12:772-8. [DOI: 10.1200/jop.2016.015818] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
74 Ansari D, Bauden M, Bergström S, Rylance R, Marko-varga G, Andersson R. Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma. British Journal of Surgery 2017;104:600-7. [DOI: 10.1002/bjs.10471] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
75 Lekka K, Tzitzi E, Giakoustidis A, Papadopoulos V, Giakoustidis D. Contemporary management of borderline resectable pancreatic ductal adenocarcinoma. Ann Hepatobiliary Pancreat Surg 2019;23:97-108. [PMID: 31225409 DOI: 10.14701/ahbps.2019.23.2.97] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]